NCT02588651View on ClinicalTrials.gov

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 17, 2016

Primary Completion Date

October 14, 2024

Study Completion Date

October 14, 2024

Conditions

T-cell LymphomaAngioimmunoblastic T-cell LymphomaHepato-splenic T-cell LymphomaAdult T-cell Leukemia/LymphomaEnteropathy Associated T-cell LymphomaNK T-cell Lymphoma

Interventions

DRUG

Brentuximab vedotin

study drug given intravenously to determine efficacy in study diseases

Trial Locations (4)

44106

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland

44195

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland

48201

Wayne State University, Karmanos Cancer Institute, Detroit

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors

lead

Deepa Jagadeesh

OTHER

NCT02588651 - A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) | Biotech Hunter | Biotech Hunter